רשימת פרסומים של המעבדה הגסטרואנטרולוגית

Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.

Ungar B, Malickova K, Hanžel J, Abu Arisha M, Paul S, Rocha C, Ben Shatach Z, Abitbol CM, Haj Natour O, Selinger L, Yavzori M, Fudim E, Picard O, Shoval I, Eliakim R, Kopylov U, Magro F, Roblin X, Chowers Y, Drobne D, Lukas M, Ben Horin S.

J Crohns Colitis. 2021 Oct 7;15(10):1707-1719.

Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease.

Levhar N, Ungar B, Kopylov U, Fudim E, Yavzori M, Picard O, Amariglio N, Chowers Y, Shemer-Avni Y, Mao R, Chen MH, Ye Z, Eliakim R, Ben-Horin S.

Inflamm Bowel Dis. 2020 Aug 20;26(9):1330-1339.

Infliximab levels and antibodies in IBD-related peripheral arthralgia.

Levartovsky A, Ungar B, Yavzori M, Picard O, Fudim E, Eliakim R, Paul S, Roblin X, Ben-Horin S, Kopylov U.

Int J Colorectal Dis. 2020 Jun;35(6):1141-1148.

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists.

Vaisman-Mentesh A, Rosenstein S, Yavzori M, Dror Y, Fudim E, Ungar B, Kopylov U, Picard O, Kigel A, Ben-Horin S, Benhar I, Wine Y.

Front Immunol. 2019 Dec 18;10:2921.

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis.

Yablecovitch D, Kopylov U, Lahat A, Amitai MM, Klang E, Ben-Ami Shor D, Neuman S, Levhar N, Fudim E, Avidan B, Laish I, Selinger L, Zingboim-Orbach N, Picard O, Yavzori M, Eliakim R, Ben-Horin S.

Therap Adv Gastroenterol. 2019 Oct 9;12:1756284819881590.

Infliximab therapy intensification upon loss of response: Is there an optimal trough level?

Ungar B, Ben-Shatach Z, Ben-Haim G, Yavzori M, Picard O, Fudim E, Kopylov U, Veyrard P, Del Tedesco É, Paul S, Eliakim R, Ben-Horin S, Roblin X.

Dig Liver Dis. 2019 Aug;51(8):1106-1111.

Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares.

Braun T, Di Segni A, BenShoshan M, Neuman S, Levhar N, Bubis M, Picard O, Sosnovski K, Efroni G, Farage Barhom S, Glick Saar E, Lahad A, Weiss B, Yablecovitch D, Lahat A, Eliakim R, Kopylov U, Ben-Horin S, Haberman Y.

Am J Gastroenterol. 2019 Jul;114(7):1142-1151.

Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.

Ben-Horin S, Van Assche G, Chowers Y, Fudim E, Ungar B, Picard O, Yavzori M, Kopylov U, Mao R, Chen MH, Peled Y, Gueta I, Eliakim R, Loebstein R, Markovits N.

J Crohns Colitis. 2018 Nov 28;12(12):1410-1417.

Characterization of hepatitis B and delta coinfection in Israel.

Shirazi R, Ram D, Rakovsky A, Bucris E, Gozlan Y, Lustig Y, Shaked-Mishan P, Picard O, Shemer-Avni Y, Ben-Zvi H, Halutz O, Lurie Y, Veizman E, Carlebach M, Braun M, Naftaly MC, Shlomai A, Safadi R, Mendelson E, Sklan EH, Ben-Ari Z, Mor O.

BMC Infect Dis. 2018 Feb 27;18(1):97. doi: 10.1186/s12879-018-3008-x.

Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.

Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.

J Pediatr Gastroenterol Nutr. 2018 Jun 12.

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The Poetic Study.

Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S.

Am J Gastroenterol. 2018 Jun 5.

Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.

Ben-Horin S, Ungar B, Kopylov U, Lahat A, Yavzori M, Fudim E, Picard O, Peled Y, Eliakim R, Del Tedesco E, Paul S, Roblin X.

Aliment Pharmacol Ther. 2018 Apr;47(8):1117-1125.

Prolonged Recurrent Abdominal Pain is Associated With Ongoing Underlying Mucosal Inflammation in Patients who had an Episode of Acute Complicated Diverticulitis.

Lahat A, Necula D, Yavzori M, Picard O, Halperin S, Eliakim R, Ben-Horin S.

J Clin Gastroenterol. 2018 Jan 19. doi: 10.

Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, Coscas D, Waterman M, Haj-Natour O, Orbach-Zingboim N, Mao R, Chen M, Chowers Y, Eliakim R, Ben-Horin S.

Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7.

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B.

Aliment Pharmacol Ther. 2018 Jan;47(2):212-218. doi: 10.1111/apt.14410. Epub 2017 Nov 9.

Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.

Lahat A, Shitrit AB, Naftali T, Milgrom Y, Elyakim R, Goldin E, Levhar N, Selinger L, Zuker T, Fudim E, Picard O, Yavzori M, Ben-Horin S.

J Crohns Colitis. 2018 Jan 5;12(1):120-123.

The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.

Fay S, Ungar B, Paul S, Levartovsky A, Yavzori M, Fudim E, Picard O, Eliakim R, Ben-Horin S, Roblin X, Kopylov U.

Inflamm Bowel Dis. 2017 Nov;23(11):1924-1929.

Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.

Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM, Lee S, Kwon KS, Lim BP, Jeon MS, Shin EC, Choi YS, Fudim E, Picard O, Yavzori M, Ben-Horin S, Chang SJ.

J Crohns Colitis. 2017 May 1;11(5):593-602. doi: 10.1093/ecco-jcc/jjw183.

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O, Lang A, Williet N, Paul S, Chowers Y, Bar-Gil Shitrit A, Eliakim R, Ben-Horin S, Roblin X.

Aliment Pharmacol Ther. 2017 Jan;45(2):276-282.

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.

Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-Horin S.

Aliment Pharmacol Ther. 2016 Jun;43(12):1293-9. doi: 10.1111/apt.13631. Epub 2016 Apr 19.

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S.

Clin Gastroenterol Hepatol. 2016 Apr;14(4):550-557.e2. doi: 10.1016/j.cgh.2015.10.025. Epub 2015 Oct 29.

Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S.

Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.

Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.

Gut. 2016 Jul;65(7):1132-8.

Significance of low level infliximab in the absence of anti-infliximab antibodies.

Ungar B, Anafy A, Yanai H, Ron Y, Yavzori M, Picard O, Fudim E, Loebstein R, Kopylov U, Chowers Y, Dotan I, Eliakim R, Ben-Horin S.

World J Gastroenterol. 2015 Feb 14;21(6):1907-14. doi: 10.3748/wjg.v21.i6.1907.

Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies.

Katz LH, Kopylov U, Fudim E, Yavzori M, Picard O, Ungar B, Eliakim R, Ben-Horin S, Chowers Y.

Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):491-8. doi: 10.1016/j.clinre.2014.01.010. Epub 2014 Mar 5.

Celiac disease resolution after allogeneic bone marrow transplantation is associated with absence of gliadin-specific memory response by donor-derived intestinal T-cells.

Ben-Horin S, Polak-Charcon S, Barshack I, Picard O, Fudim E, Yavzori M, Avivi C, Mardoukh C, Shimoni A, Chowers Y, Maor Y.

J Clin Immunol. 2013 Nov;33(8):1395-402. doi: 10.1007/s10875-013-9943-9. Epub 2013 Oct 20.

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S; ABIRISK consortium.

Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y.

Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7. doi: 10.1016/j.cgh.2012.10.020. Epub 2012 Oct 24.

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.

Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30.

Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease.

Ben-Horin S, Yavzori M, Kopylov U, Picard O, Fudim E, Eliakim R, Chowers Y, Lang A.

J Crohns Colitis. 2011 Dec;5(6):555-8. doi: 10.1016/j.crohns.2011.05.006.

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.

Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S.

Inflamm Bowel Dis. 2012 Sep;18(9):1628-33. doi: 10.1002/ibd.21919. Epub 2011 Oct 29.

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.

Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.

Adalimumab level in breast milk of a nursing mother.

Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, Lang A.

Clin Gastroenterol Hepatol. 2010 May;8(5):475-6. doi: 10.1016/j.cgh.2009.11.023. Epub 2010 Jan 6. No abstract available.

A murine model for the study of molecular pathogenesis of radiation proctitis.

Symon Z, Goldshmidt Y, Picard O, Yavzori M, Ben-Horin S, Alezra D, Barshack I, Chowers Y.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):242-50. doi: 10.1016/j.ijrobp.2009.07.1736.

Lidocaine inhibits epithelial chemokine secretion via inhibition of nuclear factor kappa B activation.

Lang A, Ben Horin S, Picard O, Fudim E, Amariglio N, Chowers Y.

Immunobiology. 2010 Apr;215(4):304-13. doi: 10.1016/j.imbio.2009.05.006. Epub 2009 Jun 26.

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.

Ben-Horin S, Goldstein I, Fudim E, Picard O, Yerushalmi Z, Barshack I, Bank I, Goldschmid Y, Meir SB, Mayer L, Chowers Y.

Gut. 2009 Mar;58(3):396-403. doi: 10.1136/gut.2008.157339. Epub 2008 Oct 2.

Functional voltage-gated sodium channels are expressed in human intestinal epithelial cells.

Barshack I, Levite M, Lang A, Fudim E, Picard O, Ben Horin S, Chowers Y.

Digestion. 2008;77(2):108-17. doi: 10.1159/000123840. Epub 2008 Apr 7.

Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation.

Lahat A, Ben-Horin S, Lang A, Fudim E, Picard O, Chowers Y.

Clin Exp Immunol. 2008 May;152(2):320-7. doi: 10.1111/j.1365-2249.2008.03636.x. Epub 2008 Mar 18. Erratum in: Clin Exp Immunol. 2008 Aug;153(2):307. Horin, SB [corrected to Ben-Horin, S].

Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients.

Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-Meir S, Colombel JF, Chowers Y.

Am J Med Genet A. 2003 Sep 1;121A(3):240-4.

>> חזרה למעבדה הגסטרואנטרולוגית